abstract: Pyridoxine (Vitamin B6) to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect

CONCLUSIONS:

Administration of pyridoxine (Vitamin B6) , at concentrations extending across possible therapeutic plasma levels in humans, does not antagonise OHP (Oxaliplatin) antitumour effects in a range of relevant tumour cell lines.

This study provides a foundation for clinical studies to test whether pyridoxine can minimise OHP-related neurotoxicity, and clinicians can be confident that pyridoxine is very unlikely to reverse the antitumour effects of OHP, as seems to be the case with Ca/Mg infusions.

This could prove to be a cost-effective way to minimise OHP-related neurotoxicity, allowing more effective less toxic treatment and better outcomes in patients.